Comment from the Editor-in-Chief on correspondence in this issue on immuno-techniques

Comment

J C McGrath. Br J Pharmacol. 2011 Jul.

. 2011 Jul;163(6):1111-2.

doi: 10.1111/j.1476-5381.2011.01261.x.

No abstract available

Comment on

Knockout controls and the specificity of cannabinoid CB2 receptor antibodies.
Ashton JC. Ashton JC. Br J Pharmacol. 2011 Jul;163(6):1113; author reply 1114. doi: 10.1111/j.1476-5381.2010.01139.x. Br J Pharmacol. 2011. PMID: 21707587 Free PMC article. No abstract available.
'Altered' mesenteric artery SK(Ca) : functional implications?
Sandow S, Grayson TH. Sandow S, et al. Br J Pharmacol. 2011 Jul;163(6):1115-7; author reply 1118-21. doi: 10.1111/j.1476-5381.2011.01262.x. Br J Pharmacol. 2011. PMID: 21707589 Free PMC article. No abstract available.

1. Ashton JC. Knockout control, and the specificity of cannabinoid CB2 receptor antibodies. Br J Pharmacol. 2011;163:1113. - PMC - PubMed
1. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol. 2010;160:467–479. - PMC - PubMed
1. Edwards G, Harno E, Porter E, Weston A. Reply by authors to letter from Sandow and Grayson. Br J Pharmacol. 2011;163:1115–1117.
1. Garland CJ. Compromised vascular endothelial cell SKCa activity: a fundamental aspect of hypertension? Br J Pharmacol. 2010;160:833–835. - PMC - PubMed
1. Michel MC, Wieland T, Tsujimoto G. How reliable are G-protein-coupled receptor antibodies? Naunyn-Schmied Arch Pharmacol. 2009;379:385–388. - PubMed